Eli Lilly | Omløpsmidler



Current Assets Endring Dato
AbbVie USD 25.58B 2.2B 2024-12
Abbott USD 23.15B 503M 2025-03
ALKERMES USD 1.48B 63.7M 2025-03
Amgen USD 26.93B 2.1B 2025-03
AstraZeneca USD 26.14B 312M 2025-03
Baxter International USD 8.85B 11M 2024-12
Biogen USD 7.63B 169.2M 2025-03
Bristol-Myers Squibb USD 30.78B 1B 2025-03
Drreddys Laboratories INR 253.02B 4.89B 2024-12
Eli Lilly USD 41.26B 8.52B 2025-03
Gilead Sciences USD 19.17B 4.39B 2024-12
GlaxoSmithKline GBP 18.08B 1.09B 2025-03
Glaxosmithkline GBP 17B 301M 2024-12
Indivior 883M 44M 2025-03
J&J USD 71.55B 15.66B 2025-03
Medtronic USD 22.51B 75M 2025-01
Merck USD 35.5B 3.28B 2025-03
Neurocrine Biosciences USD 1.72B 151.9M 2024-12
Novartis USD 29.7B 1.56B 2024-12
Novartis USD 29.7B 1.56B 2024-12
Novo Nordisk 174.4B 20.76B 2025-03
Perrigo USD 2.53B 51.1M 2025-03
Pfizer USD 45.86B 4.5B 2025-03
Prestige Brands USD 377.16M 3.54M 2024-12
Regeneron Pharmaceuticals USD 17.57B 9.64B 2025-03
Roche Holding CHF 40.04B 6.41B 2024-12
Sanofi 44.02B 1.43B 2025-03
Sanofi 42.59B 12.51B 2024-12
United Therapeutics USD 3.94B 65.9M 2025-03
Zoetis USD 5.88B 109M 2025-03



Eli Lilly Omløpsmidler - Gjeldende verdier, historiske data, prognoser, statistikk, diagrammer og økonomiske kalender - May 2025.